127 related articles for article (PubMed ID: 37540917)
1. Typology of laws restricting access to methadone treatment in the United States: A latent class analysis.
Conway A; Krawczyk N; McGaffey F; Doyle S; Baaklini V; Marshall AD; Treloar C; Davis CS; Colledge-Frisby S; Grebely J; Cerdá M
Int J Drug Policy; 2023 Sep; 119():104141. PubMed ID: 37540917
[TBL] [Abstract][Full Text] [Related]
2. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
[TBL] [Abstract][Full Text] [Related]
3. Introduction of Medicare coverage in opioid treatment programs: Findings from the first three years.
Abraham AJ; Harris SJ; Yarbrough CR
J Subst Use Addict Treat; 2024 Mar; 158():209247. PubMed ID: 38072386
[TBL] [Abstract][Full Text] [Related]
4. A trial of implementation facilitation to increase timely admission to methadone treatment.
Gryczynski J; Mitchell SG; Whitter M; Fuller D; Mitchell MM; Edelman EJ; Schwartz RP
J Subst Use Addict Treat; 2024 Jul; 162():209375. PubMed ID: 38642889
[TBL] [Abstract][Full Text] [Related]
5. Methadone dosing at New York State opioid treatment programs following initial revisions to federal regulations.
Jordan AE; Bachhuber MA; Tuazon E; Jimenez C; Lincourt P; Hussain S; Rubinfeld J; Cunningham CO
Drug Alcohol Depend; 2024 May; 258():111283. PubMed ID: 38581920
[TBL] [Abstract][Full Text] [Related]
6. Geographic variation in availability of opioid treatment programs across U.S. communities.
Jehan S; Zahnd WE; Wooten NR; Seay KD
J Addict Dis; 2024; 42(2):136-146. PubMed ID: 36645315
[TBL] [Abstract][Full Text] [Related]
7. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.
Levander XA; Pytell JD; Stoller KB; Korthuis PT; Chander G
Subst Abus; 2022; 43(1):633-639. PubMed ID: 34666636
[No Abstract] [Full Text] [Related]
8. Characteristics and current clinical practices of opioid treatment programs in the United States.
Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
[TBL] [Abstract][Full Text] [Related]
9. Changes In County-Level Access To Medications For Opioid Use Disorder After Medicare Coverage Of Methadone Treatment Began.
Harris SJ; Yarbrough CR; Abraham AJ
Health Aff (Millwood); 2023 Jul; 42(7):991-996. PubMed ID: 37406230
[TBL] [Abstract][Full Text] [Related]
10. Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states.
Patrick SW; Buntin MB; Martin PR; Scott TA; Dupont W; Richards M; Cooper WO
Subst Abus; 2019; 40(3):356-362. PubMed ID: 29949454
[No Abstract] [Full Text] [Related]
11. Dynamic changes in methadone utilisation for opioid use disorder treatment: a retrospective observational study during the COVID-19 pandemic.
Kennalley AL; Fanelli JL; Furst JA; Mynarski NJ; Jarvis MA; Nichols SD; McCall KL; Piper BJ
BMJ Open; 2023 Nov; 13(11):e074845. PubMed ID: 37973543
[TBL] [Abstract][Full Text] [Related]
12. Impact of COVID-19-related methadone regulatory flexibilities: views of state opioid treatment authorities and program staff.
Mitchell SG; Jester J; Gryczynski J; Whitter M; Fuller D; Halsted C; Schwartz RP
Addict Sci Clin Pract; 2023 Oct; 18(1):61. PubMed ID: 37848970
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of discharge reasons from methadone outpatient treatment programs.
Andraka-Christou B; Totaram R; Nguyen TD
Am J Addict; 2022 Nov; 31(6):508-516. PubMed ID: 35996855
[TBL] [Abstract][Full Text] [Related]
14. Adapting methadone inductions to the fentanyl era.
Buresh M; Nahvi S; Steiger S; Weinstein ZM
J Subst Abuse Treat; 2022 Oct; 141():108832. PubMed ID: 35870437
[TBL] [Abstract][Full Text] [Related]
15. In-Hospital Methadone Enrollment: a Novel Program to Facilitate Linkage from the Hospital to the Opioid Treatment Program for Vulnerable Patients with Opioid Use Disorder.
Calcaterra SL; Saunders S; Grimm E; Maki-Gianani E; Keniston A; Wold A; Bonaguidi A
J Gen Intern Med; 2024 Feb; 39(3):385-392. PubMed ID: 37715094
[TBL] [Abstract][Full Text] [Related]
16. Dispensing Methadone at Hospital Discharge: One Hospital's Approach to Implementing the "72-hour Rule" Change.
Skogrand E; Sharpe J; Englander H
J Addict Med; 2024 Jan-Feb 01; 18(1):71-74. PubMed ID: 37994453
[TBL] [Abstract][Full Text] [Related]
17. Pronounced Regional Disparities in United States Methadone Distribution.
Furst JA; Mynarski NJ; McCall KL; Piper BJ
Ann Pharmacother; 2022 Mar; 56(3):271-279. PubMed ID: 34184584
[TBL] [Abstract][Full Text] [Related]
18. Opioid treatment program culture and philosophy: Views of OTP staff and state officials on implementing interim methadone treatment.
Burruss-Cousins K; Mitchell SG; Gryczynski J; Whitter M; Fuller D; Ibrahim A; Schwartz RP
J Subst Use Addict Treat; 2024 Feb; 157():209265. PubMed ID: 38103832
[TBL] [Abstract][Full Text] [Related]
19. Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff.
Wu LT; Mannelli P; John WS; Anderson A; Schwartz RP
Subst Abuse Treat Prev Policy; 2023 Sep; 18(1):55. PubMed ID: 37697326
[TBL] [Abstract][Full Text] [Related]
20. Unintended consequences of methadone regulation for opioid use disorder treatment among hospitalized patients.
Calcaterra SL; Dafoe A; Tietbohl C; Thurman L; Bredenberg E
J Hosp Med; 2024 Jun; 19(6):460-467. PubMed ID: 38507276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
